Three development programs dominate the near-term agenda in metabolic disease: a challenge to Eli Lilly and Novo Nordisk's market position, an oral drug designed to mimic exercise, and a gene therapy for diabetes. Labiotech flagged all three as the bets worth tracking as the sector's capital and clinical attention concentrate.

The framing matters for portfolio planning. Lilly and Novo Nordisk currently anchor the metabolic market, and any credible challenger must clear efficacy and manufacturing bars those two incumbents set. The Labiotech analysis does not name the specific challenger or its trial data in the summary, which limits what R&D managers can act on today — the full piece carries that detail.

What are the three bets?

Labiotech groups the field's next moves into three categories:

• A race to challenge Eli Lilly and Novo Nordisk in metabolic disease.
• A pill that mimics exercise.
• A gene therapy for diabetes.

Each addresses a distinct bottleneck in current metabolic care: injectable dosing, adherence, and the durability of pharmacological control.

Why an exercise-mimicking pill?

The oral exercise mimetic is the most conceptually aggressive of the three. If a small molecule can reproduce even part of the metabolic effect of physical activity, it changes the treatment conversation for patients who cannot exercise — a population that current GLP-1-based regimens only partially serve. Labiotech's summary does not report the compound's mechanism, developer, or stage, so treat the category as a watch item rather than a near-term pipeline entry until the underlying data is reviewed.

What would a diabetes gene therapy change?

A gene therapy for diabetes would shift the disease from chronic management to potentially one-time intervention. That carries the usual gene-therapy constraints — durable manufacturing cost, delivery safety, and patient selection — but it also opens a different reimbursement conversation than daily or weekly dosing. Labiotech lists the program among its three bets without stage or sponsor detail in the summary; managers evaluating the space should read the full analysis before assigning portfolio weight.

The competitive question

The unifying thread is the Lilly-Novo duopoly. Both companies have converted incretin biology into dominant metabolic franchises, and challengers now need differentiated assets — oral delivery, gene-level intervention, or novel mechanisms — rather than head-to-head imitation. The three bets Labiotech identifies map onto those differentiation routes.

For R&D budget holders, the practical read is sequencing: exercise mimetics and metabolic gene therapies remain early and unpriced in the summary's terms, while the challenge to Lilly and Novo is already a race with defined competitors. Which of the three produces a registrational data set first will decide where the next round of licensing money lands.